BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 22434288)

  • 1. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
    Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
    Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy in urgent coronary interventions.
    Valente S; Lazzeri C; Giglioli C; Margheri M; Comeglio M; Nicolaci L; Chechi T; Gensini GF
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):737-41. PubMed ID: 17001234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine.
    Chong E; Poh KK; Liang S; Tan HC
    Ann Acad Med Singap; 2010 May; 39(5):374-80. PubMed ID: 20535427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions.
    Chou RH; Huang PH; Hsu CY; Leu HB; Huang SS; Huang CC; Chen JW; Lin SJ
    J Formos Med Assoc; 2016 Jul; 115(7):501-9. PubMed ID: 26830105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast induced nephropathy in patients with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty.
    Subedi B; Siddique MA; Zaman SM; Hasan MI; Arzu J; Awal A; Fatema K
    Mymensingh Med J; 2011 Apr; 20(2):270-4. PubMed ID: 21522099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study.
    An JN; Yoo KD; Hwang JH; Kim HL; Kim SH; Yang SH; Kim JH; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Nephrology (Carlton); 2015 Aug; 20(8):552-9. PubMed ID: 25783484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
    Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
    Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
    EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
    Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
    Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.